Eli Lilly and Company Reports Strong Q4 and Full Year 2024 Results

Eli Lilly and Company (NYSE: LLY) has announced its preliminary financial results for the fourth quarter and full year 2024, with revenue and earnings coming in at the high end of the outlook range. The company reported revenue of $13.53 billion for the quarter, up 45% year-over-year, driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue grew by 20% compared to Q4 2023. Pipeline progress included the approval of Zepbound in the U.S. for moderate-to-severe obstructive sleep apnea in adults with obesity and the approval of Omvoh in the U.S. for moderately to severely active Crohn's disease.

Q4 2024 EPS increased 102% to $4.88 on a reported basis, and 114% to $5.32 on a non-GAAP basis, both inclusive of $0.19 of acquired IPR&D charges. For the full year 2024, revenue is expected to be in the range of $58.0 billion to $61.0 billion, EPS in the range of $22.05 to $23.55, and non-GAAP EPS in the range of $22.50 to $24.00.



The company's strong performance can be attributed to its ability to manage costs and expenses effectively, as well as its focus on innovation and growth in key therapeutic areas. Eli Lilly's commitment to investing in research and development, as well as its strategic partnerships and acquisitions, have also contributed to its success.



In an interview, Eli Lilly's Chair and CEO, David A. Ricks, stated, "2024 was a highly successful year for Lilly. We had major data readouts for tirzepatide in treating chronic disease associated with obesity, invested billions more in expanding our manufacturing capacity and launched Kisunla and Ebglyss — important drivers of our long-term balanced growth outlook. We enter 2025 with tremendous momentum and look forward to strong financial performance and several important Phase 3 readouts which, if positive, will further accelerate our long-term growth."

Eli Lilly's strong financial performance, coupled with its robust pipeline and commitment to innovation, positions the company well for continued growth and success in the years to come.